ClinicalTrials.gg
RecruitingNCT07854262Updated Oct 2, 2026

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA

An interventional study of Complete Decongestive Therapy and Extracorporeal Shock Wave Therapy in Breast Cancer Related Lymphedema, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Nov 2024, registered Sep 2026).
  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Breast Cancer Lymphedema with a site in Turkey — 5 open to participants now, 7 under way, none of them phase 3. Breast Cancer Lymphedema · Turkey.

Planned enrollment
4th of 22
48 · median 40
Started
2024
with 3 others
No phase
22 of 34
4 open now
Registered
33rd of 34
by date
Lead sponsor
2 of 34
Ankara City Hospital Bilkent

Among the 34 studies in Breast Cancer Lymphedema with a site in Turkey, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 with no phase, and was the 33rd registered.

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.

Browse Breast Cancer Lymphedema studies →

Open to participants now

5 of the 34 studies in Breast Cancer Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Breast Cancer Lymphedema with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema.

Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy.

Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.

Read the detailed description

Breast cancer-related lymphedema is a chronic condition characterized by impaired lymphatic drainage, accumulation of protein-rich interstitial fluid, chronic inflammation, and progressive tissue fibrosis. Complete decongestive therapy is currently considered the standard treatment for lymphedema. However, treatment response may be insufficient in some patients, and additional physical therapy modalities may be required.

Extracorporeal shock wave therapy is a mechanotherapy modality that generates high-amplitude mechanical acoustic waves. Previous studies suggest that low-energy ESWT may promote tissue regeneration, endothelial neoangiogenesis, modulation of inflammation, reduction of pain, prevention of soft-tissue fibrosis, and lymphangiogenesis.

The present study aims to investigate whether the addition of ESWT to complete decongestive therapy provides additional clinical benefits compared with complete decongestive therapy alone in patients with breast cancer-related Stage II lymphedema.

Unlike previous studies that have primarily evaluated short-term outcomes, participants in this study will also be assessed at 3 months after completion of treatment. In addition, only patients with a lymphedema duration of less than 4 years and Stage II disease will be included. Ultrasonographic assessment of skin and subcutaneous tissue thickness will also be performed to investigate the potential effects of ESWT on tissue fibrosis.

03

Conditions studied

  • Breast Cancer Related Lymphedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Female patients with unilateral upper-extremity lymphedema related to breast cancer.

At least 2 years have elapsed since the diagnosis of breast cancer, cancer treatment has been completed, and cure has been documented during oncology follow-up.

Stage II lymphedema according to the International Society of Lymphology classification.

Duration of lymphedema of less than 4 years.

Voluntary participation in the study. -

Exclusion Criteria: Poor general health status.

Open wounds, sensory deficits, or other conditions in the treatment area that may constitute a to treatment.

Active infection.

Presence of .

Bilateral breast cancer.

Bilateral lymphedema.

Use of anticoagulant therapy or presence of a coagulation disorder.

Cognitive impairment that may prevent completion of study assessment procedures.

Physical therapy, including electrotherapy or exercise therapy, ESWT, or regular use of nonsteroidal anti-inflammatory drugs within the previous 6 months.

Systemic inflammatory or disorders such as rheumatoid arthritis or systemic lupus erythematosus.

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Complete Decongestive Therapy

    Participants in this group will receive Phase I complete decongestive therapy for three weeks. Treatment will consist of manual lymphatic drainage, multilayer short-stretch bandaging, and lymphedema exercises. Complete decongestive therapy will be administered five sessions per week for a total of 15 sessions.

    Other: Complete Decongestive Therapy

  • Experimental
    Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy

    Participants in this group will receive Phase I complete decongestive therapy together with extracorporeal shock wave therapy. Complete decongestive therapy will be administered five sessions per week for three weeks, for a total of 15 sessions. Extracorporeal shock wave therapy will be administered three sessions per week for three weeks.

    Other: Complete Decongestive Therapy · Device: Extracorporeal Shock Wave Therapy

Interventions

  • OtherComplete Decongestive Therapy

    Complete decongestive therapy will consist of manual lymphatic drainage performed by an experienced physiotherapist according to the Vodder technique for 45-60 minutes, followed by multilayer short-stretch bandaging and lymphedema exercises performed under the supervision of the physiotherapist. Treatment will be administered five sessions per week for a total of 15 sessions. Arm Cross-Reference: Complete Decongestive Therapy Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy

    Also known as: CDT

  • DeviceExtracorporeal Shock Wave Therapy

    Radial extracorporeal shock wave therapy will be administered using a pressure of 2 bar, a frequency of 4 Hz, and a total of 2,500 shocks per session. The shocks will be distributed as follows: Axillary region: 750 shocks Upper arm: 500 shocks Cubital region: 250 shocks Forearm: 500 shocks Dorsum of the hand: 500 shocks ESWT will be administered three sessions per week for three weeks. Arm Cross-Reference: Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy

    Also known as: ESWT

06

What researchers measure

Primary outcomes

  1. Change in Upper-Extremity Circumference Difference

    Circumference measurements will be obtained from both the affected and unaffected upper extremities, and the difference between the two extremities will be recorded.

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

  2. Change in Upper-Extremity Volume

    Upper-extremity volume will be calculated from serial circumference measurements using the truncated cone formula.

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

  3. Change in Skin and Subcutaneous Tissue Thickness Assessed by Ultrasonography

    Skin and subcutaneous tissue thickness will be assessed ultrasonographically at the dorsum of the hand, forearm, and upper arm.

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

Secondary outcomes

  1. Change in Upper-Extremity Function Assessed by the QuickDASH

    Upper-extremity functional status will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire.

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

  2. Change in Lymphedema-Related Quality of Life Assessed by LYMQOL

    Lymphedema-related quality of life will be assessed using the Lymphedema Quality of Life Questionnaire (LYMQOL).

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

  3. Change in Upper-Extremity Pain Assessed by Visual Analog Scale

    Upper-extremity pain experienced during the previous week will be evaluated using a Visual Analog Scale (VAS).

    Time frame: Baseline, immediately after completion of the 3-week treatment, 1 month after treatment, and 3 months after treatment.

07

Study locations

1 of 1 sites recruiting
  • Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
    Ankara, Turkey (Türkiye)
    Recruiting
    • ŞEBNEM ÖVER, MD · Contactsebnemfahli@gmail.com · 05422477954
    • şebnem över, MD · Sub investigator
    • sibel ünsal delialioğlu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data (IPD) with other researchers. The study protocol does not include an IPD-sharing plan.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2026, 22 months after the start.

Of 66 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 22 months is above that.

Counting every sponsor, half of 69 studies reached it within 18 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Nov 20, 2024
Primary completionEst.
Oct 14, 2026
CompletionEst.
Oct 14, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854262
Responsible party
Şebnem Fahlioğulları (Physical Medicine and Rehabilitation Resident Physician, Ankara City Hospital Bilkent) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 20, 2024
Primary completion
Oct 14, 2026 (estimated)
Completion
Oct 14, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

şebnem över, MD
Contact
sebnemfahli@gmail.com
05422477954
sibel ünsal delialioğlu, MD
principal investigator · Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion